Last reviewed · How we verify
Interferon Inoculation
At a glance
| Generic name | Interferon Inoculation |
|---|---|
| Sponsor | BriaCell Therapeutics Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
- Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 (NA)
- AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer (PHASE2)
- Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA
- A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer (PHASE1, PHASE2)
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (PHASE4)
- BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon Inoculation CI brief — competitive landscape report
- Interferon Inoculation updates RSS · CI watch RSS
- BriaCell Therapeutics Corporation portfolio CI